Overall, the observed effects of imatinib in NSCLC are consistent with the inhibition of PDGFR-β; these changes in the microenvironment, including decreased IFP and modified vasculature, result in improved drug delivery and efficacy in the preclinical setting. Here, PDGFRB is linked to non-small cell lung carcinoma.